Piper Sandler Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,013.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by equities researchers at Piper Sandler from $1,195.00 to $1,013.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price target would indicate a potential upside of 46.71% from the company’s previous close.

REGN has been the subject of several other research reports. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. Oppenheimer decreased their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Finally, Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,006.71.

Regeneron Pharmaceuticals Trading Up 2.2 %

Shares of REGN stock traded up $14.68 during mid-day trading on Monday, hitting $690.47. The company’s stock had a trading volume of 174,977 shares, compared to its average volume of 866,894. Regeneron Pharmaceuticals has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company’s fifty day simple moving average is $727.19 and its 200-day simple moving average is $936.01. The company has a market cap of $75.88 billion, a PE ratio of 17.10, a P/E/G ratio of 1.59 and a beta of 0.10.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of the company. Adirondack Trust Co. grew its stake in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 10 shares during the period. UMB Bank n.a. increased its holdings in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after buying an additional 10 shares during the last quarter. Trust Co. of Vermont raised its position in Regeneron Pharmaceuticals by 8.3% in the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 12 shares during the period. Nvwm LLC grew its position in shares of Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after acquiring an additional 14 shares during the period. Finally, Moss Adams Wealth Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.6% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 15 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.